DeCure for Salivary gland mucoepidermoid carcinoma
DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for salivary gland mucoepidermoid carcinoma — screening already-approved drugs against its 29-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSalivary gland mucoepidermoid carcinoma maps to a 29-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for salivary gland mucoepidermoid carcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
Cbl proto-oncogene B (CBLB) — CBLB is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 4-methyl-1,2,4-triazol-3-yldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8QTG · 1.419 Å · ligand 3-[3-[3-methyl-1-(4-methyl-1,2,4-triazol-3-yl)cyclobutyl]phenyl]-5-(trifluoromethyl)-1~{H}-pyridin-2-one (WUQ). Experimental structure, not a prediction.
What the evidence adds up to
Mucoepidermoid carcinoma is the most common malignant tumour of the salivary gland, representing 3 to 5% of all gland tumours and 20 to 30% of malignant tumours in minor salivary glands. One case report describes a 12-year-old child with a hard palate MEC, where early diagnosis, multidisciplinary evaluation, and intraoral surgical treatment were considered key determinants of good outcome. Another report describes a 50-year-old man with a 2.5 cm ulcer-budding tumour of the soft palate, movable relative to the deep plane; complete surgical excision is stated as the treatment of choice, combined with postoperative radiotherapy and chemotherapy. Cutaneous presentation of MEC is described as rare and infrequent, with prognosis related to histological grade and clinical outcome.
No abstract provides any quantitative survival or response rate data. No abstract reports a clinical trial, a prospective cohort, or a comparison of treatment regimens. No abstract mentions any drug by name, let alone a repurposed drug. The evidence consists entirely of single-case reports and a literature review that restates standard management.
What is missing is any trial testing a systemic therapy, any data on drug response in advanced or recurrent disease, any patient stratification by molecular subtype or grade, and any funding for a prospective study. Without these, no drug can be evaluated for repurposing in salivary gland mucoepidermoid carcinoma.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Revista da Faculdade de Ciências Médicas de Sorocaba · 2016 · 2 citations · open access
Carcinoma mucoepidermoide: caso raro em paciente jovem
AbstractThe mucoepidermoid carcinoma (MEC) is considered the most common malignant tumor of salivary gland and represents 3 to 5% of all tumors glands. For its aggressive behavior, it must be considered among the diagnostic hypotheses in regions where they can have salivary glands. Early diagnosis and appropriate tumor management are a priority for good survival, quality of life and even cure. This work reports a case of MEC of hard palate in a 12 years child. Early diagnosis, multidisciplinary evaluation and intra oral surgical treatment were key determinants of good outcomes in patients with MEC of minor salivary gland.
Primary high grade mucoepidermoid carcinoma of skin and cervical lymphatic affection a rare entity
AbstractMucoepidermoid carcinoma is a well documented and described in the salivary glands entity, represents 20-30% of malignant tumors in minor salivary glands and multiple tumors have been reported in head and neck, paranasal sinuses, upper respiratory airways, thyroid, breast, in our experience and based on the literature, its cutaneous presentation is rare and infrequent, but identifiable by pathology and immunohistochemistry not very different from the salivary glands; Prognosis is related to histological grade, clinical outcome.
Journal of Clinical Case Studies Reviews & Reports · 2022 · 0 citations · open access
Mucoepidermoid Carcinoma of the Palate: A Case Report and Literature Review
AbstractMucoepidermoid carcinoma (MEC) is the epithelial salivary gland neoplasm of the oral cavity. The most common pathological type for the salivary gland tumors of the head and neck was mucoepidermoid carcinoma. In our work, we report a case of mucoepidermoid carcinoma observed in a 50-year-old man. Clinically, he presented the ulcer-budding tumor of the soft palate, movable relative to the deep plan measuring 2,5 cm. The diagnosis was based on clinical, radiological and pathological arguments. Complete surgical excision is the treatment of choice in combination with postoperative radiotherapy and chemotherapy.
South Asian Research Journal of Oral and Dental Sciences · 2022 · 0 citations · open access
Mucoepidermoid Carcinoma of the Palate: A Case Report and Literature Review
AbstractMucoepidermoid carcinoma (MEC) is the epithelial salivary gland neoplasm of the oral cavity. The most common pathological type for the salivary gland tumors of the head and neck was mucoepidermoid carcinoma. In our work, we report a case of mucoepidermoid carcinoma observed in a 50-year-old man. Clinically, he presented the ulcer-budding tumor of the soft palate, movable relative to the deep plan measuring 2,5 cm. The diagnosis was based on clinical, radiological and pathological arguments. Complete surgical excision is the treatment of choice in combination with postoperative radiotherapy and chemotherapy.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
